Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer Previously Exposed to Inhibitors of the PI3K Pathway: A Phase II Study With Pharmacodynamics Markers
Phase of Trial: Phase II
Latest Information Update: 02 Jan 2017
At a glance
- Drugs Palbociclib (Primary) ; Fulvestrant; Tamoxifen
- Indications Breast cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 28 Dec 2016 Planned End Date changed from 1 Aug 2017 to 1 Aug 2020.
- 28 Dec 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2018.